{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-01-06T12:27:00.223404+00:00",
  "news": [
    {
      "title": "AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMUtNeXAxZWhJV1Y1S3N3cWR3OC1CS0YxSF9yNXZ6TThtOUdzN1dlUS1CaHhfaWQxRE1CUVVaWXFGVW4yR1lxdGtGRkNpZVptdGhuNTVrUHFDRFZ5cTNIT2w1c0RvM1c2Qm5mbnMyYWdCNHhEVWpPZWNxV3ZvQ1lkNWYtOWVBMWZKcm1ocFVzVkxMQThRUW5WM0NJR0VpbGdFeGxGOWhHSHQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMUtNeXAxZWhJV1Y1S3N3cWR3OC1CS0YxSF9yNXZ6TThtOUdzN1dlUS1CaHhfaWQxRE1CUVVaWXFGVW4yR1lxdGtGRkNpZVptdGhuNTVrUHFDRFZ5cTNIT2w1c0RvM1c2Qm5mbnMyYWdCNHhEVWpPZWNxV3ZvQ1lkNWYtOWVBMWZKcm1ocFVzVkxMQThRUW5WM0NJR0VpbGdFeGxGOWhHSHQ?oc=5\" target=\"_blank\">AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2026-01-05T13:11:31+00:00",
      "source": "BioSpace"
    },
    {
      "title": "AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS - PR Newswire",
      "link": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQcWpiRG9leU85RUVNSFpKeE5kQ1FrTlRCcnc1V3lqM05nbGdtLTREUUNPUlRmZVZQQVFlXzI1b2VPN2Z1bTlCdlN6UUxhN3YwanhaZTdHQ2lXNEtfdVJXdTVJM1ZPUXVDeENVV1NjbnhlbHVDMnpjQzMweFVsNmk5U2diRV8zbGpBdGZQRzk0eHp3SmFHOXhhZTZkQXlnMDdkd1FPa1JwN1ZFVlZrb1Y1UGdLOURHZy1wVmFmQWZ5clFRUnJIT0F2MGlFb2NNdDZKYlBfdmM3ZVBubGdmOGwyYUNxV3o?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQcWpiRG9leU85RUVNSFpKeE5kQ1FrTlRCcnc1V3lqM05nbGdtLTREUUNPUlRmZVZQQVFlXzI1b2VPN2Z1bTlCdlN6UUxhN3YwanhaZTdHQ2lXNEtfdVJXdTVJM1ZPUXVDeENVV1NjbnhlbHVDMnpjQzMweFVsNmk5U2diRV8zbGpBdGZQRzk0eHp3SmFHOXhhZTZkQXlnMDdkd1FPa1JwN1ZFVlZrb1Y1UGdLOURHZy1wVmFmQWZ5clFRUnJIT0F2MGlFb2NNdDZKYlBfdmM3ZVBubGdmOGwyYUNxV3o?oc=5\" target=\"_blank\">AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire</font>",
      "published": "2025-12-19T08:00:00+00:00",
      "source": "PR Newswire"
    },
    {
      "title": "Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News",
      "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSVE3NTB6ejFEeUlQM2p4MW1aRExwY1QxS3JNaGFsS290UGsxdVlaRGVNSlVPVEhTeXhLejd5bVJ6VWFuSTBRTlhITldUMWZjMnlEV1FYbE90RjZ0ZER3YktTOEpveHdDQjVEdDFtSnBEYVQ3WlJ1QnJCM1JfQzZmY1dPc290blZjNnRadkZGOE5feWdfT2xjYXhDVnlHUnh1QkVBWmQwWGw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSVE3NTB6ejFEeUlQM2p4MW1aRExwY1QxS3JNaGFsS290UGsxdVlaRGVNSlVPVEhTeXhLejd5bVJ6VWFuSTBRTlhITldUMWZjMnlEV1FYbE90RjZ0ZER3YktTOEpveHdDQjVEdDFtSnBEYVQ3WlJ1QnJCM1JfQzZmY1dPc290blZjNnRadkZGOE5feWdfT2xjYXhDVnlHUnh1QkVBWmQwWGw?oc=5\" target=\"_blank\">Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MedCity News</font>",
      "published": "2026-01-05T19:07:01+00:00",
      "source": "MedCity News"
    },
    {
      "title": "2025 at Amgen: Investing, Expanding, and Serving More Patients - Amgen",
      "link": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcWprWDR1WDBZZHhaOHM3NVBFRXlsd3d2UTRQQjU2cnlmS2hkVEFSb1lJX3A1dUlvbnZrRVZ1N0lXTXJsWGVNeWRXZ0d1T0t0Z0F0d2g3RzlWOXRnM1Ffa3FhVTloLW5yNmMzcGNCWURtN3ZBVU1lT0RING5tc3cxX284Z2JBVk14VlREWDJlRDF4MS1weHBtU2tzYlRvZw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMingFBVV95cUxOcWprWDR1WDBZZHhaOHM3NVBFRXlsd3d2UTRQQjU2cnlmS2hkVEFSb1lJX3A1dUlvbnZrRVZ1N0lXTXJsWGVNeWRXZ0d1T0t0Z0F0d2g3RzlWOXRnM1Ffa3FhVTloLW5yNmMzcGNCWURtN3ZBVU1lT0RING5tc3cxX284Z2JBVk14VlREWDJlRDF4MS1weHBtU2tzYlRvZw?oc=5\" target=\"_blank\">2025 at Amgen: Investing, Expanding, and Serving More Patients</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Amgen</font>",
      "published": "2025-12-17T08:00:00+00:00",
      "source": "Amgen"
    },
    {
      "title": "Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOTXB4MW05ekxRRERxVnZTUE85QkV4dk1EM0YzTERFN0NDYkFqODExUXdzdnBFT0x3MU0xbnhjVmdZZzduWkVfcEhYeVZuc0NXaER3NWhhT1pIV1N6VjltRTBXaHdJb1V4VzVEOXdIa09VVE9iNnZsV2ZMN3dpMjJCTWU1Yw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigwFBVV95cUxOTXB4MW05ekxRRERxVnZTUE85QkV4dk1EM0YzTERFN0NDYkFqODExUXdzdnBFT0x3MU0xbnhjVmdZZzduWkVfcEhYeVZuc0NXaER3NWhhT1pIV1N6VjltRTBXaHdJb1V4VzVEOXdIa09VVE9iNnZsV2ZMN3dpMjJCTWU1Yw?oc=5\" target=\"_blank\">Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2026-01-05T23:00:03+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit - Fierce Biotech",
      "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWFNCSHNFOXotRmJyZDhzWnlLRzB0bnQ5eG1wSDk2bGJDa2wtX3g2M0RBWW5ZT0E5aU0zdGZBclRoTlJJNFQ1UHpfSVpkX3VXZklyN2lxV0sycHFrRFpINnNld2ZFMVpFZDlMejlKdHFsLWppZjYtQUVoMi1vUE1ncWZKWHQycjFxWFVaN1dmRFJmZVhLdEN0dnR5blFPRDdfUFg4ekptTFVWSTRfdWx2TjgtQTRqWm8?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMitwFBVV95cUxNWFNCSHNFOXotRmJyZDhzWnlLRzB0bnQ5eG1wSDk2bGJDa2wtX3g2M0RBWW5ZT0E5aU0zdGZBclRoTlJJNFQ1UHpfSVpkX3VXZklyN2lxV0sycHFrRFpINnNld2ZFMVpFZDlMejlKdHFsLWppZjYtQUVoMi1vUE1ncWZKWHQycjFxWFVaN1dmRFJmZVhLdEN0dnR5blFPRDdfUFg4ekptTFVWSTRfdWx2TjgtQTRqWm8?oc=5\" target=\"_blank\">Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>",
      "published": "2026-01-05T14:30:00+00:00",
      "source": "Fierce Biotech"
    },
    {
      "title": "What to Expect From Amgen's Q4 2025 Earnings Report - Barchart.com",
      "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOeHZoQTdfQmpUN29ZelkwdGFUREswU3VIVjN4eDlONUxvYUNNNHZHWHlydDY0MjNjaTkzajEyUU9RM1RzLUNkbE1pWDd0VjhjVWNwX2pyTnBnNFZ2OC13NmdCdllpN1NJRVlLVGRVcmREUFZxZUxELVd1ZGdTbjhhaXhfOTc4UDdPUGFjOXE3bUg2VTVXZzh6QmRid1A?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMinAFBVV95cUxOeHZoQTdfQmpUN29ZelkwdGFUREswU3VIVjN4eDlONUxvYUNNNHZHWHlydDY0MjNjaTkzajEyUU9RM1RzLUNkbE1pWDd0VjhjVWNwX2pyTnBnNFZ2OC13NmdCdllpN1NJRVlLVGRVcmREUFZxZUxELVd1ZGdTbjhhaXhfOTc4UDdPUGFjOXE3bUg2VTVXZzh6QmRid1A?oc=5\" target=\"_blank\">What to Expect From Amgen's Q4 2025 Earnings Report</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Barchart.com</font>",
      "published": "2026-01-06T12:01:17+00:00",
      "source": "Barchart.com"
    },
    {
      "title": "Zenas BioPharma Shares Decline After Obexelimab Trial Results Show Lower Effectiveness Compared to Amgen Treatment - geneonline.com",
      "link": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUGIxYkpKcHdNREZkTG0zYWRqQmtubkZkUm1EaGVwdzFyT2o5aHZxMHVyQUI3QXhjMXQ5Z1h4dlIzY1J3ZEhlX1B0MGFVYllmSkZQUlBwZnh5OVhyNHVJVGtfdUJ6X3laUWRwbDhHLVY5dDlnclVfLWF5Q0lUYnhKNlZ6UjFSeXFtSDdzQXd4bXZzbTV5cFIxcEthWV9qUTUwWDRpMmVXek5UQ1lzaG1OckVibXN4NkoyWnVQQTE5NXo2anlJTzZVd245dF9zVWdJTnc0aHRfc2hBUQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUGIxYkpKcHdNREZkTG0zYWRqQmtubkZkUm1EaGVwdzFyT2o5aHZxMHVyQUI3QXhjMXQ5Z1h4dlIzY1J3ZEhlX1B0MGFVYllmSkZQUlBwZnh5OVhyNHVJVGtfdUJ6X3laUWRwbDhHLVY5dDlnclVfLWF5Q0lUYnhKNlZ6UjFSeXFtSDdzQXd4bXZzbTV5cFIxcEthWV9qUTUwWDRpMmVXek5UQ1lzaG1OckVibXN4NkoyWnVQQTE5NXo2anlJTzZVd245dF9zVWdJTnc0aHRfc2hBUQ?oc=5\" target=\"_blank\">Zenas BioPharma Shares Decline After Obexelimab Trial Results Show Lower Effectiveness Compared to Amgen Treatment</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">geneonline.com</font>",
      "published": "2026-01-05T17:35:00+00:00",
      "source": "geneonline.com"
    }
  ],
  "product_launches": [
    {
      "title": "Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5\" target=\"_blank\">Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-09-10T07:00:00+00:00",
      "source": "BioSpace"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    },
    {
      "title": "Strong first-quarter product sales for Amgen - The Pharma Letter",
      "link": "https://news.google.com/rss/articles/CBMiggFBVV95cUxObE5kVHJ3TmlvdEhBTmplQjgtVEVfdE1LQ1hmcmw2UThFaTg4aVk4eEtMbjdPR0dabHBaM0dMczZ5MlB2QWlxaDBCcXh3ZkRDWFVpbVRDMjQxbXdNS2JrYzFQYWd5ZWw3S0ZEcGdGRTRKRFE3eWszOFFkX1A0QWpfdkxB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiggFBVV95cUxObE5kVHJ3TmlvdEhBTmplQjgtVEVfdE1LQ1hmcmw2UThFaTg4aVk4eEtMbjdPR0dabHBaM0dMczZ5MlB2QWlxaDBCcXh3ZkRDWFVpbVRDMjQxbXdNS2JrYzFQYWd5ZWw3S0ZEcGdGRTRKRFE3eWszOFFkX1A0QWpfdkxB?oc=5\" target=\"_blank\">Strong first-quarter product sales for Amgen</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Pharma Letter</font>",
      "published": "2025-05-02T07:00:00+00:00",
      "source": "The Pharma Letter"
    },
    {
      "title": "3 major patent losses this year — and a key strategy to fill the gaps - Pharma Voice",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5\" target=\"_blank\">3 major patent losses this year — and a key strategy to fill the gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Pharma Voice</font>",
      "published": "2025-07-21T07:00:00+00:00",
      "source": "Pharma Voice"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-01-05",
      "close": 320.7200012207031
    },
    "history": [
      {
        "date": "2025-12-24",
        "close": 333.9599914550781
      },
      {
        "date": "2025-12-26",
        "close": 332.92999267578125
      },
      {
        "date": "2025-12-29",
        "close": 329.6300048828125
      },
      {
        "date": "2025-12-30",
        "close": 328.69000244140625
      },
      {
        "date": "2025-12-31",
        "close": 327.30999755859375
      },
      {
        "date": "2026-01-02",
        "close": 327.6400146484375
      },
      {
        "date": "2026-01-05",
        "close": 320.7200012207031
      }
    ],
    "name": "Amgen Inc."
  }
}